The article describes the potential of oral small molecule GLP-1 agonists as an alternative to injectable peptide-based therapies in the treatment of type 2 diabetes mellitus and obesity. Oral peptide GLP‑1 agonists, such as oral semaglutide, are limited by low oral bioavailability, the need for dietary restriction, and precise timing of administration[1]. Peptide oral forms are also more expensive to manufacture and require refrigeration[1]. The development of oral small molecule agonists could address the limitations of injectable therapies including needle phobia and injection site reactions[1]. The authors emphasize that the oral form could improve patient acceptability due to easier use and storage[1]. However, the article does not report the results of a specific clinical trial with a small molecule oral agonist or precise statistics on the efficacy of these molecules; the information is a commentary on the potential of such therapy[1].